Overview

Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer

Status:
Unknown status

Trial end date:
2017-12-31

Target enrollment:

Participant gender:

Summary

Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens

Phase:

Phase 2

Details

Lead Sponsor:

BioLab 612 LLC

Collaborator:

Cleveland BioLabs, Inc.